GlaxoSmithKline announces non-core OTC products to be divested

GlaxoSmithKline announces non-core OTC products to be divested
Issued: Thursday 14 April 2011, London UK


GSK today identified the non-core OTC brands that it intends to divest as the company focuses its Consumer Healthcare business around a portfolio of fast-growing priority brands and the emerging markets.  GSK's intention to divest its non-core Consumer assets was announced at the company's fourth quarter 2010 results on 3rd February 2011.

The products to be divested, which are primarily sold in Europe and the United States, had sales in 2010 of approximately £500 million, 10% of GSK's total Consumer Healthcare turnover.  They include analgesics:  Solpadeine, BC and Goody's; vitamin and supplement product Abtei; feminine hygiene treatment Lactacyd; and alli for weight management. 

Individually, the brands to be divested have strong heritage and good prospects, but GSK has lacked sufficient critical mass in some product categories and certain brands have lacked focus due to other global priorities. GSK therefore believes that other companies are better placed to maximise the potential they offer.

The process of communicating with interested parties will begin over the next few weeks, with the aim of divesting the products by late 2011, subject to interest and realising appropriate value for shareholders.

Following the divestment, GSK's Consumer Healthcare business will focus on three priority categories: Oral Health, Wellness/OTC and Nutrition, in which the company has fast-growing leading brands such as Sensodyne, Panadol and Horlicks.  On a pro forma basis, the retained business delivered sales of approximately £4.5 billion in 2010, and grew at 6% CAGR over the period 2007-2010. The refocused business will hold market-leading positions in Smoking Control, Denture Care, Dental Sensitivity, Analgesics, and Nutrition.  

Commenting on the proposed divestment, CEO of GSK Andrew Witty said:  "Consumer Healthcare is a key growth driver for GSK.  But it is important that we focus this business around product categories, brands and markets where we have most depth and competitive advantage, with the best prospects for strong growth.  This divestment is also an example of our commitment to focus on realising value and enhancing returns to shareholders."

Note to editors:

Brands to be divested include the following products with sales of more than £5 million per annum.  The intention is to divest these products in all markets in which they are sold by GSK:
 
Abtei, vitamins, minerals and supplements

alli, weight management

Beano, gastro-intestinal

BC, analgesic

Beconase, respiratory

Debrox, ear wax cleanser

Dequadin, cough/cold

Ecotrin, analgesics

FiberChoice, dietary supplement
  
 Goody's, analgesics
Granufink, urological

Lactacyd, feminine hygiene

Libenar, respiratory

Nytol, sleep aid

Phillips MOM, gastro-intestinal

Solpadeine, analgesics

Tagamet/Stomedine, gastro-intestinal

Valda, cough/cold supplement

Zantac OTC, gastro-intestinal
 

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com.

GlaxoSmithKline Enquiries:
  
  
 
UK Media enquiries:
 David Mawdsley
 (020) 8047 5502
 
 
 Alexandra Harrison
 (020) 8047 5502
 
 
  
  
 
US Media enquiries:
 Nancy Pekarek
 (919) 483 2839
 
 
 Mary Anne Rhyne
 (919) 483 2839
 
 
 Kevin Colgan
 (919) 483 2839
 
 
 Sarah Alspach
 (919) 483 2839
 
 
  
  
 
European Analyst/Investor enquiries:
 Sally Ferguson
 (020) 8047 5543
 
 
 Gary Davies
 (020) 8047 5503
 
 
 Ziba Shamsi
 (020) 8047 3289
 
 
  
  
 
US Analyst/ Investor enquiries:
 Tom Curry
 (215) 751 5419
 
 
 Jeff McLaughlin
 (215) 751 7002
 
UK Trade Media enquiries:
 Emma Boran
 (020) 8047 4221
 
 
 Claire Dixon
 (020) 8047 4296
 
 
 Iona Maclean
 (020) 8047 4239
 
US Trade Media enquiries:
 Malesia Dunn
 (412) 200 3544
 
 
 Debbie Bolding
 (973) 889 2344
 

 

GlaxoSmithKline cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK's operations are described under 'Risk Factors' in the 'Business Review' in the company's Annual Report on Form 20-F for 2010.

Suggested Articles

Novartis is rolling out positive interim phase 3 data on Zolgensma in Europe, which could support the recent launch of the SMA gene therapy there.

The new cost-cutting goal comes on top of a €2.6 billion annual savings target the company already laid out in a revamp initiated in 2018.

As hearings continued on Capitol Hill, a congressional committee said Novartis, Amgen and Mallinckrodt used routine price hikes to meet sales targets.